<DOC>
	<DOCNO>NCT01854632</DOCNO>
	<brief_summary>This study provide Senegal Ministry Health data clinical efficacy Live-Attenuated Influenza Vaccine ( LAIV ) . This data inform future policy consideration influenza vaccine .</brief_summary>
	<brief_title>Clinical Efficacy Trivalent Live-Attenuated Influenza Vaccine ( LAIV ) Among Children Senegal</brief_title>
	<detailed_description>This study double-blind , individual-randomized , placebo-controlled , clinical efficacy trial among healthy child age 24 71 month Niakhar area Senegal . A total 1,761 healthy child randomize 2:1 ratio LAIV placebo . For evaluation efficacy , passive active surveillance conduct weekly throughout study identify outcome among vaccinated subject . Children meet protocol-defined clinical case definition nasal swab throat swab specimen collect test rRT-PCR evidence influenza virus infection . 100 1,761 participant also include substudy design evaluate virologic evidence LAIV replication . As , nasal throat swab specimen collect day 0 ( prior vaccination ) , well post-vaccination day 2 , 4 subject include substudy . These specimen test presence wild-type vaccine virus . Additionally , detailed assessment vaccine reactogenicity make among child actively collect solicit unsolicited reaction study visit week post vaccination ( day 2 4 ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female child least 24 month age old 71 month age time study vaccination . A child whose parent guardian 's primary residence , time study vaccination , within Niakhar DSS intend present area duration trial . A child whose parent legal guardian willing provide write informed consent prior participant 's study vaccination Serious , active , medical condition , include : chronic disease body system , chronic infection tuberculosis , genetic disorder , Down 's syndrome cytogenetic disorder , know suspected disease immune system kind . History documented hypersensitivity eggs component vaccine ( include gelatin , sorbitol , lactalbumin chicken protein ) , lifethreatening reaction previous influenza vaccination . History GuillainBarré syndrome . Receipt immunosuppressive agent , include systemic corticosteroid , month plan study vaccination . Receipt aspirin therapy aspirincontaining therapy within two week plan study vaccination . History severe allergic reaction generalize urticarial , angioedema , anaphylaxis . Receipt influenza vaccine within past 12 month . Has condition determine investigator likely interfere evaluation vaccine significant potential health risk child make unlikely child would complete study . Temporary Contraindications : Acute illness accompany body temperature 37.5°C ( axillary measurement ) within 14 day enrollment visit . Any acute respiratory infection within 14 day enrollment visit . Any illness accompany active wheezing within 14 day enrollment visit .</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>71 Months</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>influenza vaccine</keyword>
	<keyword>trivalent live-attenuated influenza vaccine</keyword>
	<keyword>efficacy</keyword>
	<keyword>Africa</keyword>
	<keyword>Senegal</keyword>
</DOC>